British Columbia Adds Insulins To Its Biosimilar Switching Policy

Canadian Province Says Patients Have Six Months To Make The Transition

 
• By Chloe Kent
  
British Columbia and Canada flags
British Columbia’s biosimilar switching policy now includes Humalog and NovoRapid • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products